The origin of many diseases such as Alzheimer's or Parkinson's can be found at the molecular level in our body, in other ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

Neurodegenerative diseases of aging like Parkinson's disease (PD) or Alzheimer's disease (AD) are usually not diagnosed until ...